Novavax Inc. (NASDAQ:NVAX) went up by 0.37% from its latest closing price compared to the recent 1-year high of $189.40. The company’s stock price has collected 6.68% of gains in the last five trading sessions. MarketWatch.com reported 4 hours ago that There are seven coronavirus vaccine candidates being tested in the U.S. — here’s where they stand
Is It Worth Investing in Novavax Inc. (NASDAQ :NVAX) Right Now?
Plus, the 36-month beta value for NVAX is at 1.39. Opinions of the stock are interesting as 3 analysts out of 5 who provided ratings for Novavax Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 2 rated it as “hold,” and 0 as “sell.”
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The average price from analysts is $227.60. NVAX currently public float of 55.24M and currently shorts hold a 14.86% ratio of that float. Today, the average trading volume of NVAX was 7.35M shares.
NVAX’s Market Performance
NVAX stocks went up by 6.68% for the week, with a monthly drop of -1.80% and a quarterly performance of 35.95%, while its annual performance rate touched 2062.67%. The volatility ratio for the week stands at 9.18% while the volatility levels for the past 30 days are set at 10.21% for Novavax Inc.. The simple moving average for the period of the last 20 days is 3.83% for NVAX stocks with a simple moving average of 103.09% for the last 200 days.
Analysts’ Opinion of NVAX
Many brokerage firms have already submitted their reports for NVAX stocks, with H.C. Wainwright repeating the rating for NVAX by listing it as a “Buy.” The predicted price for NVAX in the upcoming period, according to H.C. Wainwright is $290 based on the research report published on August 06th of the current year 2020.
JP Morgan, on the other hand, stated in their research note that they expect to see NVAX reach a price target of $275. The rating they have provided for NVAX stocks is “Overweight” according to the report published on August 05th, 2020.
Ladenburg Thalmann gave a rating of “Sell” to NVAX, setting the target price at $105 in the report published on August 05th of the current year.
NVAX Trading at -14.41% from the 50-Day Moving Average
After a stumble in the market that brought NVAX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.79% of loss for the given period.
Volatility was left at 10.21%, however, over the last 30 days, the volatility rate increased by 9.18%, as shares surge +3.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.99% lower at present.
During the last 5 trading sessions, NVAX rose by +6.68%, which changed the moving average for the period of 200-days by +2,588.59% in comparison to the 20-day moving average, which settled at $104.51. In addition, Novavax Inc. saw 2622.36% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at NVAX starting from Erck Stanley C, who sale 4,112 shares at the price of $107.80 back on Sep 29. After this action, Erck Stanley C now owns 32,727 shares of Novavax Inc., valued at $443,267 using the latest closing price.
Trizzino John, the EVP, CBO and CFO of Novavax Inc., sale 18,321 shares at $107.29 during a trade that took place back on Sep 29, which means that Trizzino John is holding 7,337 shares at $1,965,630 based on the most recent closing price.
Stock Fundamentals for NVAX
Current profitability levels for the company are sitting at:
- -694.44 for the present operating margin
The net margin for Novavax Inc. stands at -711.04. The total capital return value is set at -87.24, while invested capital returns managed to touch -89.70. Equity return is now at value 173.30, with -23.30 for asset returns.
When we switch over and look at the enterrpise to sales, we see a ratio of 18.54, with the company’s debt to enterprise value settled at 0.96. The receivables turnover for the company is 4.98 and the total asset turnover is 0.10. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.77.